BTK and immune system disorder: Some studies have shown that even in the presence of comorbidities or immune dysfunction, the efficacy of targeted therapies (such as BTK inhibitors or BCL-2 inhibitors) remains favorable, and response rates and progression-free survival are not significantly associated with these factors (24, 25).